July 15th 2025
Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months, respectively, in patients with platinum-resistant ovarian cancer.
Senaparib Significantly Improves PFS Vs Placebo in Advanced Ovarian Cancer
October 20th 2023Results from the phase 3 FLAMES trial show an improved progression-free survival benefit with senaparib monotherapy vs placebo across all pre-specified patient subgroups with newly diagnosed, advanced ovarian cancer.
TTFields Combo Misses OS End Point in Platinum-Resistant Ovarian Cancer
August 28th 2023Findings from an exploratory subgroup analysis in the phase 3 INNOVATE-3 trial suggest that Tumor Treating Fields plus paclitaxel may confer a survival benefit in patients who received only 1 prior line of therapy for platinum-resistant ovarian cancer.
Mirvetuximab Benefit Confirmed in MIRASOL Trial in Frα+ Ovarian Cancer
July 1st 2023Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer
June 19th 2023Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.
Mirvetuximab Soravtansine Shows Survival Benefit in Ovarian Cancer Subtype
May 4th 2023Based on findings from the phase 3 MIRASOL trial, investigators plan to submit a supplemental biologics license application for mirvetuximab soravtansine in folate receptor α–positive platinum-resistant ovarian cancer.